No Prescription |
 |
 | ||
|
MISOPT Cosopt |
|
| ||
No Prescription » Prescription Drugs 11 » MISOPT Cosopt Cosopt lowers high pressure in the eye a problem typically caused by the condition known as open-angle glaucoma. Cosopt works by reducing production of the liquid that fills the eyeball. Dorzolamide ophthalmic reduces the amount of fluid in the eye which decreases pressure inside the eye. Timolol ophthalmic is a beta-blocker that also reduces pressure inside the eye.The combination of dorzolamide and timolol ophthalmic is used to treat certain types of glaucoma and other causes of high pressure inside the eye. Buy MISOPT Cosopt and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About MISOPT Cosopt: Product Type: Prescription Drugs 11 MISOPT ( Cosopt Dorzox-T Generic Dorzolamide/Timolol ) MISOPT (Cosopt Dorzox-T Generic Dorzolamide/Timolol) Cosopt Dorzox-T Generic Dorzolamide/Timolol 20mg/5mg Cosopt Dorzox-T Generic Dorzolamide/Timolol MISOPT
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
